Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Skip to Content

Darolutamide in the Treatment of Non-Metastatic Castration Resistant Prostate Cancer & Darolutamide in Combination with Docetaxel for Metastatic Hormone Sensitive Prostate Cancer

Download PQI pdf 1.28MB

Last Updated: June 1, 2023

By: Stockton Hematology Oncology Medical Group, CA | The American Oncology Network

About this PQI in Action

In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a precise and concise peer-reviewed clinical guidance resource for healthcare professionals. By providing Quality Standards and effective practices around specific aspects of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet simple resource for managing patients receiving oral or intravenous anti-cancer agents. This PQI in Action is a follow up to the NUBEQA® (darolutamide) PQIs. It explores how the medically integrated teams at Stockton Hematology Oncology Medical Group and The American Oncology Network (AON) incorporate PQIs as part of their daily workflow. It will discuss how utilizing the Darolutamide In the Treatment of Non-Metastatic Castration Resistant Prostate Cancer and the Darolutamide in combination with Docetaxel for Metastatic Hormone Sensitive Prostate Cancer PQIs elevates patient care and experience.